anyone else notice survodutide kicking in around week 93
Six-word version is the title — anyone else notice survodutide kicking in around week 93 — and the rest is context.
Read the phase 2 hepatic paper properly and the endpoint definitions were more interesting than the headline response rate.
Sent a vial to Janoshik because there was nothing on file. 99.6% against a claimed 99.0%. First entry for this compound in my own log.
If two or three other people have done the same thing we might actually learn something. Alone it is an anecdote.
best — the order this archive was captured in
The honest evidence position, written out so this board does not drift.
Phase 2 data exists in a specific, biopsy-characterised population, with a slow protocol escalation and tolerability tables worth reading in full. Nothing containing this compound is approved by any regulator anywhere. Research-use-only material is not approved for human use.
Independent purity results across this entire site number in the low single figures. That means nobody here — including the people who post most confidently — has a basis for statements about batch-to-batch consistency. If you test something, post it; the log is the only thing that will change that position.
Is that a weight number from a different programme?
Yes — nothing containing this is approved anywhere, which is the first fact and usually the last one mentioned.